Vivos Therapeutics

Vivos Therapeutics
Vivos Therapeutics
VVOS
NASDAQ
2.71 USD
-41.85%

About

Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as obstructive sleep apnea (OSA) and snoring in adults. The Company calls its solution The Vivos Method.

The Vivos Method represents the first clinically effective nonsurgical, noninvasive and nonpharmaceutical solution for treating mild to severe OSA. The Vivos Method includes treatment regimens that employ the proprietary Complete Airway Repositioning and/or Expansion (CARE) appliance therapy and other modalities that alter the size, shape and position of the soft tissues that comprise a patient's upper airway and/or palate.

The Vivos Method comprises various products and services, including Vivos CARE oral appliance therapy, Vivos oral appliances and therapies outside of CARE system, Vivos AireO2, and Vivos Airway Intelligence Service..

Financials Amount (in millions)

Income statement
Balance sheet
Cash flow

Ratios

Price and Volume
Volume
Ten Day Average Volume 82.8K
Three Month Average Volume 1.3M
High Low
Fifty-Two Week High 48.79 USD
Fifty-Two Week Low 1.91 USD
Fifty-Two Week High Date 29 Nov 2023
Fifty-Two Week Low Date 30 May 2024
Price and Volume
Current Price 2.71 USD
Beta 8
Relative Price Change
Four Week Relative Price Change 22.15%
Thirteen Week Relative Price Change 21.15%
Twenty-Six Week Relative Price Change -55.11%
Fifty-Two Week Relative Price Change -65.58%
Year-to-Date Relative Price Change -81.60%
Price Change
One Day Price Change -6.23%
Thirteen Week Price Change 29.67%
Twenty-Six Week Price Change -50.64%
Five Day Price Change 0.18%
Fifty-Two Week Price Change -56.86%
Year-to-Date Price Change -78.22%
Month-to-Date Price Change 17.82%
Per Share Data
Book Value
Book Value Per Share (Last Fiscal Year) 0.22411 USD
Book Value Per Share (Most Recent Quarter) 1.86595 USD
Tangible Book Value Per Share (Last Fiscal Year) -1.55517 USD
Tangible Book Value Per Share (Most Recent Quarter) 0.91401 USD
EBITD
EBITD Per Share (Trailing Twelve Months) -6.27659 USD
Revenue
Revenue Per Share (Last Fiscal Year) 11.31805 USD
Revenue Per Share (Trailing Twelve Months) 6.87903 USD
Dividend
Dividend Per Share (Last Fiscal Year) -99999.99 USD
Dividend Per Share (Trailing Twelve Months) 0 USD
Dividend Per Share (5 Year) -99999.99 USD
Earnings Per Share
Excluding Extraordinary Items (Last Fiscal Year) -11.13926 USD
Excluding Extraordinary Items (Trailing Twelve Months) -6.97622 USD
Normalized (Last Fiscal Year) -11.13926 USD
Basic Excluding Extraordinary Items (Last Fiscal Year) -11.13926 USD
Basic Excluding Extraordinary Items (Trailing Twelve Months) -6.97622 USD
Including Extraordinary Items (Last Fiscal Year) -11.13926 USD
Including Extraordinary Items (Trailing Twelve Months) -6.97622 USD
Cash
Cash Per Share (Last Fiscal Year) 0.89591 USD
Cash Per Share (Most Recent Quarter) 2.0294 USD
Cash Flow Per Share (Last Fiscal Year) -10.4832 USD
Cash Flow Per Share (Trailing Twelve Months) -5.56573 USD
Free Cash Flow Per Share (Trailing Twelve Months) -5.71143 USD
Margins
Cash Flow Revenue
Cash Flow Revenue (5 Year) -88
Cash Flow Revenue (Trailing Twelve Months) -83
Pretax Margin
Pretax Margin (Trailing Twelve Months) -85.90%
Pretax Margin (Last Fiscal Year) -98.42%
Pretax Margin (5 Year) -113.15%
Gross Margin
Gross Margin (Last Fiscal Year) 59.93%
Gross Margin (Trailing Twelve Months) 60.08%
Gross Margin (5 Year) 70.20%
Operating Margin
Operating Margin (Last Fiscal Year) -125.32%
Operating Margin (Trailing Twelve Months) -96.23%
Operating Margin (5 Year) -118.17%
Net Profit Margin
Net Profit Margin (Last Fiscal Year) -98.42%
Net Profit Margin (Trailing Twelve Months) -85.90%
Net Profit Margin (5 Year) -113.15%
Growth
Book Value
Book Value Per Share (5 Year) -50.80%
Tangible Book Value (5 Year) -99,999.99%
Free Operating Cash Flow
Free Operating Cash Flow (5 Year) -99,999.99%
Revenue
Revenue Change MRQ vs 1 Year Ago 19.41%
Revenue Growth (3 Year) 29.48%
Revenue Change (Trailing Twelve Months) -9.23%
Revenue Per Share Growth 15.88%
Revenue Growth (5 Year) 1.84%
Capital Spending Debt
Capital Spending (5 Year) -8.48%
Total Debt (5 Year) -99,999.99%
Dividends
Dividend Growth (3 Year) -99,999.99%
Earnings Per Share
EPS Change MRQ vs 1 Year Ago 87.05%
EPS Change (Trailing Twelve Months) 63.95%
EPS Growth (3 Year) -99,999.99%
EPS Growth (5 Year) -99,999.99%
EBITDA
EBITDA (5 Year) -99,999.99%
EBITDA (5 Year Interim) -99,999.99%
Net Profit Margin
Net Profit Margin Growth (5 Year) -99,999.99%
Valuation
Total Price to Book
Price to Tangible Book (Last Fiscal Year) -100,000
Price to Tangible Book (Most Recent Quarter) 3
Price to Free Cash Flow
Price to Free Cash Per Share (Last Fiscal Year) -100,000
Price to Free Cash Per Share (Trailing Twelve Months) -100,000
Net Debt
Net Debt (Most Recent Quarter) -6,903,000
Net Debt (Last Fiscal Year) -1,643,000
Price to Sales
Price to Sales (Last Fiscal Year) 1
Price to Sales (Trailing Twelve Months) 1
Price to Earnings
PE Excluding Extraordinary Items (Last Fiscal Year) -100,000
PE Normalized (Last Fiscal Year) -100,000
PE Basic Excluding Extraordinary Items (Trailing Twelve Months) -100,000
PE Excluding Extraordinary Items High (Trailing Twelve Months) -100,000
PE Excluding Extraordinary Items Low (Trailing Twelve Months) -100,000
PE Including Extraordinary Items (Trailing Twelve Months) -100,000
Dividends
Dividend Yield (5 Year) -99,999.99%
Dividend Yield -99,999.99%
Current Dividend Yield 0.00%
Price to Book
Price to Book (Last Fiscal Year) 12
Price to Book (Most Recent Quarter) 1
Financial Strength
Debt to Equity
Long Term Debt to Equity (Last Fiscal Year) 0
Long Term Debt to Equity (Most Recent Quarter) 0
Payout Ratio
Payout Ratio (Last Fiscal Year) -99,999.99%
Payout Ratio (Trailing Twelve Months) -99,999.99%
Quick Ratio
Quick Ratio (Last Fiscal Year) -100,000
Quick Ratio (Most Recent Quarter) -100,000
Enterprise Value
Current Enterprise Value to Free Cash Flow (Last Fiscal Year) -100,000
Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) -100,000
Current Ratio
Current Ratio (Last Fiscal Year) 0
Current Ratio (Most Recent Quarter) 1
Free Cash Flow
Free Cash Flow (Last Fiscal Year) -12,749,000
Free Cash Flow (Trailing Twelve Months) -11,642,000
Net Interest Coverage
Net Interest Coverage (Last Fiscal Year) -100,000
Net Interest Coverage (Trailing Twelve Months) -100,000
Total Debt to Equity
Total Debt to Equity (Last Fiscal Year) 0
Total Debt to Equity (Most Recent Quarter) 0
Management Effectiveness
Return on Assets
Return on Assets (Last Fiscal Year) -111.11%
Return on Assets (Trailing Twelve Months) -81.41%
Return on Assets (5 Year) -89.72%
Return on Equity
Return on Equity (Last Fiscal Year) -521.22%
Return on Equity (Trailing Twelve Months) -284.99%
Return on Equity (5 Year) -171.58%
Return on Investment
Return on Investment (Last Fiscal Year) -262.52%
Return on Investment (Trailing Twelve Months) -166.05%
Return on Investment (5 Year) -149.70%

Cookie Settings

We use cookies to deliver and improve our services, analyze site usage, and if you agree, to customize or personalize your experience and market our services to you. You can read our Cookie Policy here.